Department of Pathology, Stony Brook University Medical Center, Stony Brook, NY 11794, USA.
J Immunol. 2012 Mar 1;188(5):2380-6. doi: 10.4049/jimmunol.1102454. Epub 2012 Jan 27.
HMGB1 is a chromatin architectural protein that is released by dead or damaged cells at sites of tissue injury. Extracellular HMGB1 functions as a proinflammatory cytokine and chemoattractant for immune effector and progenitor cells. Previously, we have shown that the inhibitor of NF-κB kinase (IKK)β- and IKKα-dependent NF-κB signaling pathways are simultaneously required for cell migration to HMGB1. The IKKβ-dependent canonical pathway is needed to maintain expression of receptor for advanced glycation end products, the ubiquitously expressed receptor for HMGB1, but the target of the IKKα non-canonical pathway was not known. In this study, we show that the IKKα-dependent p52/RelB noncanonical pathway is critical to sustain CXCL12/SDF1 production in order for cells to migrate toward HMGB1. Using both mouse bone marrow-derived macrophages and mouse embryo fibroblasts (MEFs), it was observed that neutralization of CXCL12 by a CXCL12 mAb completely eliminated chemotaxis to HMGB1. In addition, the HMGB1 migration defect of IKKα KO and p52 KO cells could be rescued by adding recombinant CXCL12 to cells. Moreover, p52 KO MEFs stably transduced with a GFP retroviral vector that enforces physiologic expression of CXCL12 also showed near normal migration toward HMGB1. Finally, both AMD3100, a specific antagonist of CXCL12's G protein-coupled receptor CXCR4, and an anti-CXCR4 Ab blocked HMGB1 chemotactic responses. These results indicate that HMGB1-CXCL12 interplay drives cell migration toward HMGB1 by engaging receptors of both chemoattractants. This novel requirement for a second receptor-ligand pair enhances our understanding of the molecular mechanisms regulating HMGB1-dependent cell recruitment to sites of tissue injury.
高迁移率族蛋白 B1(HMGB1)是一种染色质结构蛋白,在组织损伤部位由死亡或受损细胞释放。细胞外 HMGB1 作为一种促炎细胞因子和趋化因子,作用于免疫效应细胞和祖细胞。之前,我们已经表明,核因子-κB 激酶(IKK)β和 IKKα依赖性核因子-κB 信号通路同时需要细胞迁移到 HMGB1。IKKβ依赖性经典途径需要维持晚期糖基化终产物受体(HMGB1 的广泛表达受体)的表达,但 IKKα非经典途径的靶标尚不清楚。在这项研究中,我们表明 IKKα依赖性 p52/RelB 非经典途径对于维持趋化因子 CXCL12/SDF1 的产生至关重要,以使细胞向 HMGB1 迁移。使用小鼠骨髓来源的巨噬细胞和小鼠胚胎成纤维细胞(MEF),观察到用 CXCL12 mAb 中和 CXCL12 完全消除了对 HMGB1 的趋化作用。此外,IKKα KO 和 p52 KO 细胞的 HMGB1 迁移缺陷可以通过向细胞添加重组 CXCL12 来挽救。此外,用 GFP 逆转录病毒载体稳定转导 p52 KO MEF,该载体强制表达 CXCL12,也显示出对 HMGB1 的近乎正常的迁移。最后,CXCL12 的 G 蛋白偶联受体 CXCR4 的特异性拮抗剂 AMD3100 和抗 CXCR4 Ab 均阻断了 HMGB1 的趋化反应。这些结果表明,HMGB1-CXCL12 相互作用通过结合两种趋化因子的受体来驱动细胞向 HMGB1 迁移。这一对新的第二受体-配体对的需求增强了我们对调节 HMGB1 依赖性细胞募集到组织损伤部位的分子机制的理解。